Search Results - clinical specialty > oncology

17 Results Sort By:
Method of targeting liposomes to bone marrow
UT Health San Antonio and Waseda University in Shinjuku, Japan have collaboratively developed a drug delivery system capable of delivering a cargo preferentially to bone marrow. This drug delivery system shows promise for therapeutic and diagnostic applications for which the cells of the bone marrow play an important role. Background:Targeted ant...
Published: 10/16/2018   |   Inventor(s): William Phillips, Beth Goins, Keitaro Sou, Shinji Takeoka, Eishun Tsuchida
Keywords(s): Biologics, Drugs
Category(s): Clinical Specialty > Oncology, Therapeutics > Biologics, Therapeutics > Other
Novel Polygodial Analogs to Treat Cancer
Novel polygodial analogs for the treatment of cancer and other proliferative diseases have been developed by researchers at UT Health San Antonio. These analogs are effective in inhibiting cell proliferation both in vitro and in vivo, without the observable side effects attributed to the parent compound. Moreover, these analogs may have potential a...
Published: 10/16/2018   |   Inventor(s): Cara Gonzales, Alex Kornienko, Ramesh Dasari
Category(s): Clinical Specialty > Dentistry, Clinical Specialty > Oncology, Therapeutics > Small Molecule
PARP-1 Inhibitor Nanoparticle and Treatment Method for Ewing Sarcoma
A novel nanoparticle formulation of an existing PARP-1 inhibitor and an associated administration regimen has been developed for the treatment of Ewing Sarcoma. This technology allows the therapeutic treatment to be targeted to the tumors, resulting in reduced required doses and system toxicity.Background:Ewing Sarcoma is rare cancer of the bone t...
Published: 10/10/2018   |   Inventor(s): Raushan Kurmasheva, Kytai Nguyen
Category(s): Clinical Specialty > Orphan Diseases, Clinical Specialty > Orthopedics, Therapeutics > Nanoparticles, Clinical Specialty > Oncology, Therapeutics > Small Molecule
Micro-RNA Therapy for High-Risk Pediatric Brain Cancer
A MicroRNA therapy has been developed for the purpose of increasing the chemo- and radio-sensitivity of tumor cells in Medulloblastoma. The invention would allow for lower dosages of radiation and chemotherapy by working synergistically with these therapies, thus reducing adverse side effects. It may also lead to more complete eradication of the tu...
Published: 9/25/2018   |   Inventor(s): Manjeet Rao, Nourhan Abdelfattah
Category(s): Therapeutics > Biologics, Therapeutics > Nucleic Acids, Clinical Specialty > Neurology, Clinical Specialty > Oncology, Clinical Specialty > Pediatrics
Novel Capsazepine Analogs to Treat Cancer
Novel compounds have been developed based upon the capsazepine pharmacophore that are effective in halting tumor cell proliferation in vitro and in vivo. Capsazepine is a known, off-patent, analog of Capsaicin that has been proposed and studied as a TRPV1 antagonist for treatment of pain. Although Capsazepine has been proposed for alleviation of p...
Published: 8/23/2018   |   Inventor(s): Cara Gonzales, Stanton McHardy
Category(s): Clinical Specialty > Oncology, Therapeutics > Small Molecule
Inducing Chemotherapeutic Sensitivity in Hyper-Transcription Diseases
This discovery is a method for the induction of sensitivity in tumor cells to a synergistic combination of PARP1 and ATR inhibition. It is applicable to hyper-transcription diseases , primarily cancers, including: Ewing sarcoma, acute myeloid leukemia, breast cancer, myelodysplastic syndrome, and possibly even Alzheimers and ALS. Background:Modern ...
Published: 8/23/2018   |   Inventor(s): Alexander Bishop, Aparna Gorthi, Carolina Romero, Liesl Lawrence, CPRIT
Category(s): Clinical Specialty > Hematology, Clinical Specialty > Oncology, Clinical Specialty > Orthopedics, Diagnostics > Biomarkers, Diagnostics > Assay
Novel Compounds to Inhibit Cancer, Cancer Metastasis, and Autoimmune Diseases
Several candidate small molecules have been discovered that show dose-dependent anti-cancer effects in vitro. These compounds each have one of the following characteristics: (1) non-hydrolyzable ATP analog or (2) adenosine receptor antagonist. Testing of these compounds has demonstrated successful inhibition of cancer cell migration. Additionally...
Published: 5/22/2018   |   Inventor(s): Jean Jiang
Category(s): Clinical Specialty > Immunology, Clinical Specialty > Oncology, Therapeutics > Small Molecule
Intravenous Tramadol for Treatment of anti-NMDA Encephalitis
The invention is a combinatorial therapy used to enhance the efficacy of plasma exchange (PLEX) in treating patients with anti-NMDAR encephalitis. This treatment regimen would treat both the psychiatric and immunological manifestations of this disorder and substantially lower the patients’ recovery periods. Background:Anti-NMDAR encephalitis ...
Published: 4/20/2018   |   Inventor(s): Ali Seifi
Category(s): Therapeutics > Small Molecule, Clinical Specialty > Neurology, Clinical Specialty > Oncology, Clinical Specialty > Immunology
Combination of DHA and HDACIs in treating Prostate Cancer
The disclosed invention is a proposed combination therapy to treat prostate cancer, especially prostate cancer patients with biochemical recurrence (BCR). The combination therapy is composed of UTH1, a fatty acid compound with Generally Recognized As Safe (GRAS) status, and Valproic Acid (VPA), a generic drug with clinical use since 1963 as a mood ...
Published: 3/9/2018   |   Inventor(s): Wasim Chowdhury, Ronald Rodriguez, Md Rahman
Category(s): Therapeutics > Small Molecule, Clinical Specialty > Oncology, Clinical Specialty > Reproductive Health, Clinical Specialty > Urology
ANGPTL4 as prognostic marker for bladder cancer
Researchers at UT Health SA have discovered a less invasive method to monitor for recurrence of bladder cancer. Using Angiopoietin-like 4 protein (ANGPTL4) as a prognostic indicator, clinicians would be able to use a urine sample to monitor the likelihood of recurrence of non-muscle invasive bladder cancer. Background:Non-muscle invasive bladder ca...
Published: 3/6/2018   |   Inventor(s): Rita Ghosh, Roble Bedolla, Eduardo Cardenas, Neelam Mukherjee, Tiffani Houston
Category(s): Diagnostics > Biomarkers, Clinical Specialty > Oncology, Clinical Specialty > Urology
1 2